Centers | ||
|
|
|
Therapeutic Accelerator Program (TAP) | EU-OPENSCREEN | BLAVATNIK CENTER for Drug Discovery |
Test |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
The BLAVATNIK CENTER for Drug Discovery (BCDD) is a fully integrated center for translational research, based at Tel Aviv University, that comprises medicinal chemistry, biological target identification and computer-assisted drug design units under... Read more |
Partnerships |
Events |
Jobs |
Novo Nordisk and Oxford to Develop Drugs to Treat Rheumatoid Arthritis and Other Inflammatory DiseasesNovo Nordisk and Kennedy Institute of Rheumatology at Oxford University have entered into partnership to develop new drugs to treat Rheumatoid Arthritis and other inflammatory disorders. Novo Nordisk will provide research funding support to ten... View all JDRF & Novo Nordisk to Collaborate on Type 1 DiabetesJDRF and Novo Nordisk have entered into collaboration to develop new immunotherapies to treat Type 1 diabetes. The new partnership will be based out of Novo's newly opened Type 1 Diabetes R&D Center in Seattle. JDRF and Novo Nordisk will be... View all UCB Partners with Oxford UniversityUCB has entered into a research and development partnership with Oxford University in Neurology and Immunology areas. UCB will provide 3.6 million pounds to Oxford scientists over a period of three year to conduct research. View all |
No EVENTS for listing |
No Job Posts |
